Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglikozide derived antibiotics

Biochimie

Volumn 88, Issue 5, 2006, Pages 565-574

  Sinan, Selma ^a   Kockar, Feray ^a   Arslan, Oktay ^a  

^a BALIKESIR UNIVERSITY   (Turkey)

Author keywords

Cefazolin sodium; Gentamycin sulfate; Inhibition; PON1; Purification

Indexed keywords

1 NAPHTHYLAMINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMMONIUM SULFATE; ARYLDIALKYLPHOSPHATASE 1; CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; GENTAMICIN; LIVER ENZYME; SEPHAROSE; TYROSINE;

ANIMAL TISSUE; ARTICLE; CHROMATOGRAPHY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME PURIFICATION; HEPATOMA CELL; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRECIPITATION;

AMMONIUM SULFATE; ANIMALS; ANTI-BACTERIAL AGENTS; ARYLDIALKYLPHOSPHATASE; CEFAZOLIN; CELL LINE, TUMOR; CELL SURVIVAL; CEPHALOSPORINS; CHROMATOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; GENTAMICINS; HUMANS; HYDROLYSIS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAMUSCULAR; KINETICS; LIVER; MICE;

EID: 33745030576     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2005.12.004     Document Type: Article

References (50)

1. Durringhton P.N., Mackness B., and Mackness M.J. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 473-480
2. (a) L.G. Costa, W.F. Li, R.J. Richter, et al., PON1 and organophosphate toxicity, See Ref. 2b, pp. (2002) 165-83. (b) L.G. Costa, C.E. Furlong, Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Norwell, MA: Kluwer Acad (2002).
3. Eckerson H.W., Wyte C.M., and La Du B.N. The human serum paraoxonase / arylesterase polymorphism. Am. J. Hum. Genet. 35 6 (1983) 1126-1138
4. Primo-Parmo S.L., Sorenson R.S., Teiber J., and La Du B.N. The human serum paraoxonase/arylesterase gen (PON1) is one member of a multigene family. Genomics 33 (1996) 498-507
5. La Du B., Aviram N., Billecke S., Navab M., Primo-Parmo S., Sorenson R.C., and Standiford T.J. On the physiological role(s) of the paraoxonases. Chem. Biol. Interact. 119-120 (1999) 379-388
6. Mochizuki H., Scherer S.W., Xi T., Nickle D.J., Majer M., Huizenga J.J., Tsui L.C., and Prochazka M. Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 213 (1998) 149-157
7. Mackness M.I., Arrol S., and Durringhton P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286 (1991) 152-154
8. Reddy S.T., Wadleigh D.J., Grijalva V., Ng C., Hama S., Gangopadhyay A., Shih D.M., Lusis A.J., Navab M., and Fogelman A.M. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 542-547
9. Sorenson R.C., Bisgaier C.L., Aviram M., Hsu C., Billecke S., and La Du B.N. Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs binding phospholipids: apolipoprotein A-1 stabilizes activity. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 2214-2225
10. Shih D.M., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
11. Draganov D.I., and La Du B. Pharmacogenetics of paraoxonases: a brief review, Naunyn Schmiedebergs. Arch. Pharmacol. 369 (2004) 78-88
12. Richter R.J., and Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmogenetics 9 (1999) 745-753
13. 55 genotype. Atheroscler. Thromb. Vasc. Biol. 20 (2000) 2441-2447
14. Billecke S., Draganov D., Councell R., Stetson P., Watson C., Hsu C., and La Du B.N. Human serum paraoxonase (PON1) isozymes Q and R hydrolyse lactones and cyclic carbonate esters. Drug Metab. Dispos. 28 (2000) 1335-1342
15. Draganov D.I., Stetson P.L., Watson C.E., Billecke S.S., and La Du B.N. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J. Biol. Chem. 275 (2000) 33435-33442
16. Tougou K., Nakamura A., Watanabe S., et al. Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a newantibacterial agent. Drug Metab. Dispos. 26 (1998) 355-359
17. Mounter L.A., Floyd C.S., Chanutin A., and Di{dotless}alkylfluorophosphatase Of Ki{dotless}dney I. Puri{dotless}fi{dotless}cati{dotless}on And Properti{dotless}es. J. Biol. Chem. 204 (1953) 221-232
18. Furlong C.E., Costa L.G., Hasett C., Richter R.J., Sundstrom J.A., Adler D.A., Disteche C.M., Omiecinski C.J., Crabb J.W., and Humbert R. Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem. Biol. İnteract. 87 (1993) 35-48
19. Gan K.N., Smolen A., Eckerson H.W., and La Du B.N. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19 (1991) 100-106
20. Mazur A. An Enzyme In Animal Tissues Capable of Hydrolyzing The Phosphorus-Fluorine Bond of Alkyl Fluorophosphates J. Biol. Chem. 164 (1946) 271-289
21. Main A.R. The role of A- esterase in the acute toxicity of paraoxon, TEPP and parathion. Can. J. Biochem. Physiol. 34 (1956) 197
22. Rodrigo L., Gil F., Hernandez A.F., Marina A., Vazquez J., and Pla A. Purification and characterization of paraoxon hydrolyse from Rat Liver. Biochem. J. 321 (1997) 595-601
23. Rodrigo L., Gil F., Hernandez F.A., Lopez O., and Pla A. Identification of paraoxonase 3 in rat liver microsomes, Purification and biochemical properties. Biochem. J. Imm. Pub. 15 (2003) (376, 261-8)
24. Malin R., Laaksonen R., Knuuti J., et al. Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. Pharmacogenetics 11 (2001) 625-633 (137:123-37)
25. Tomas M., Senti M., Garcia-Faria F., Vila J., Torrents A., Covas M., and Marrugat J. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2113-2119
26. Leviev I., and James R. Simvastatin increases plasma levels of the antioxidant enzyme paraoxonase by PON1 gene activation. Atherosclerosis 151 (2000) 41
27. Gouedard C., Koum-Besson N., Barouki R., and Morel Y. Opposite regulation of the human paraoxonase-1 gene PON1 by fenofibrate and statins. Mol. Pharmacol. 63 (2003) 945
28. Beltowski J., Wojcicka G., and Jamroz A. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) or tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities. J. Cardiovasc. Pharmacol. 43 (2004) 121
29. Radic Z., and Reiner E. Effect of atropine on esterases from human blood and pig liver. Acta Pharm. Jugosl. 36 (1986) 1
30. Blatter-Garin M.C., Kalix B., De Pre S., and James R.W. Aspirin use is associated with higher serum concentrations of the antioxidant enzyme, paraoxonase-1. Diabetologia 46 (2003) 593
31. Ali B., Zhang Q., Lim Y.K., Feng D., Retnam L., and Lim S.K. Expression of major HDL-associated antioxidant PON1 is gender dependent and regulated during inflammation. Free Radic. Biol. Med. 34 (2003) 824
32. Umeki S. Anti-inflammatory action of gentamycin through inhibitory effect on neutrophil NADPH oxidase activity. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 110 4 (1995) 817
33. Beydemir S., Kulacoglu D., Ciftçi F., and Küfrevioglu Ö..I.. The effects of some antibiotics on sheep lens glucose 6-phosphate dehydrogenase in vitro. Eur. J. Ophthalmol. 13 (2003) 155
34. Çoban A.T., Nalbantoglu B., Çi{dotless}l M.Y., Özdemi{dotless}r H., and Küfrevioǧlu O.I. Investigation of the Inhibition Effects of Some Antibiotics on Human Erythrocyte Carbonic Anhydrase Isozymes. Tr. J. Med. Sci. 28 (1998) 407
35. Bradford M.M. A rapid and sensitive method for the quantition of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-251
36. Laemmli U.K. Cleavage of structual proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
37. Foka P., Irvine S.A., Kockar F., and Ramji D.P. Interleukin-6 represses the transcription of the CCAAT/enhancer binding protein-α in hepatoma cells by inhibiting its ability to autoactivate the proximal promoter region. Nucleic Acids Res. 31 (2003) 6722-6732
38. Gil F., Pla A., Gonzalvo M.C., Hernández A.F., and Villanueva E. Partial purification of paraoxonase from rat liver. Chem. Biol. Interact. 87 (1993) 69
39. Furlong C.E., Richter R.J., Chapline C., and Crabb J.W. Purification of Rabbit and Human Serum Paraoxonase. Biochemistry 30 (1991) 10133-10140
40. Hassett C., Richter R.J., Humbert R., Chapline C., Crabb J.W., Omiecinski C.J., and Furlong C.E. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 30 (1991) 10141
41. Zimmerman J.K., Grothusen J.R., Bryson P.K., and Brown T.M. Partial purification and characterization of paraoxonase from rabbit serum. "Enzymes Hydrolyzing Organophosphorus Compounds" (1989), Ellis Horwood Ltd, Chichester, UK 128-142
42. Hochster R.M., Kates M., and Quastel J.H. Metabolic inhibitors (1972), Academic Pres, New York (and 197;3 and 4:71-89 and 66-82)
43. Reiner E., Simeon-Rudolf V., and Skrinjaric-Spoljar M. Catalytic properties and distribution profiles of paraoxonase and cholinesterase phenotypes in human sera. Toxicol. Lett. 82,83 (1995) 447-452
44. Pellin M., Moretto A., Lotti M., and Vilanova E. Distribution and biochemical properties of rat paraoxonase activity. Neurotoxicol. Teratol. 12 (1990) 611-614
45. Beydemir Ş., Kulaçoǧlu D.N., Çiftçi M., and Küfrevioǧlu Ö.İ. The effects of some antibiotics on sheep lens glucose 6-phosphate dehydrogenase in vitro. Eur. J. Ophthalmol. 13 2 (2003) 155-161
46. Erat M., Sakiroglu H., and Ciftci M. Purification and characterization of glutathione reductase from bovine erythrocytes. Prep. Biochem. Biotechnol. 33 4 (2003) 283
47. Çiftçi M., Türkoǧlu V., and Aldemir S. "Effects of some antibiotics on glucose 6-phosphate dehydrogenase in sheep liver", Vet. Med-Czech 47 (2002) 283
48. Bargota R.S., Akhtar M., Biggadike K., Gani D., and Allemann R.K. Structure-Activity Relationship on Human Serum Paraoxonase (PON1) using Substrate Analogues and Inhibitors Bioorganic. Med. Chem. Lett. 13 (2003) 1623-1626
49. Bargota Gonzalvo M.C., Gil F., Hernandez A.F., Villanueva E., and Pla A. Inhibition of Paraoxonase Activity in Human Liver Microsomes by Exposure to EDTA, Metals and Mercurials. Chemico-Biological Interactions 105 (1997) 169-179
50. Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., Erogul J., Hsu C., Dunlop C., and La Du B.N. "Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities. Selective action of human paraoxonase allozymes Q and R". Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1617